Angelalign Technology First Half 2025 Earnings: Revenues Beat Expectations, EPS In Line

Angelalign Technology (HKG:6699) First Half 2025 Results

Key Financial Results

• Revenue: US$161.4m (up 36% from 1H 2024).
• Net income: US$14.6m (up 373% from 1H 2024).
• Profit margin: 9.1% (up from 2.6% in 1H 2024). The increase in margin was driven by higher revenue.
• EPS: US$0.087 (up from US$0.018 in 1H 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Angelalign Technology Revenues Beat Expectations

Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are up 11% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Angelalign Technology's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.